Key Takeaways
- • Breakthrough Properties completed a $3 billion fundraise for life sciences real estate, exceeding its $1.5 billion target by 100% and establishing the largest dedicated real estate fund in the life sciences sector (excluding recapitalizations).
- • The joint venture between real estate developer Tishman Speyer and Bellco Capital will deploy capital across biotechnology, pharmaceuticals, medical technology, genetics, and medical equipment campuses in the United States and Europe.
- • Capital will support both existing projects and new development initiatives, positioning the fund to capture demand from high-growth biotech and corporate biopharma industries seeking specialized real estate environments.
- • Dan Belldegrun, Breakthrough co-founder and CEO, cited strong post-pandemic performance in life sciences as validation of the sector's resilience and long-term investment potential across both financial returns and public health outcomes.
Summary
Breakthrough Properties, a joint venture between real estate mogul Tishman Speyer and Bellco Capital, has successfully closed a $3 billion fundraise dedicated to developing and acquiring specialized real estate for the life sciences sector. The capital raise significantly exceeded the fund's initial $1.5 billion target and represents the largest real estate fund focused exclusively on life sciences according to CBRE and JLL, when excluding recapitalizations of existing portfolios.
The fund targets a broad ecosystem within life sciences, including biotechnology firms, pharmaceutical companies, medical technology developers, genetics research operations, and medical equipment manufacturers. Capital will be deployed across two strategic directions: financing existing projects already in Breakthrough's portfolio and funding new campus development and acquisition opportunities throughout the United States and Europe. This geographic and sectoral diversification reflects the global nature of life sciences innovation and manufacturing.
Breakthrough's leadership attributed the fundraise's success to demonstrated market strength in the life sciences sector. Dan Belldegrun, co-founder and CEO, stated that the company established the fund "with the aim of creating and operating cutting-edge environments where life science entrepreneurs and researchers can optimize their quest for life-saving treatments." Belldegrun emphasized that the past two years have validated life sciences as both a financially sound and socially impactful investment area, noting that the fund would continue developing specialized facilities offering comprehensive support services tailored to the long-term operational needs of biotech innovators.
The oversubscription of this fund reflects institutional investor confidence in the life sciences real estate thesis, capitalizing on sustained demand from high-growth biotechnology and corporate biopharma sectors seeking purpose-built laboratory and manufacturing facilities. The scale of this raise signals that specialized life sciences real estate has matured into a distinct asset class attracting significant capital from both real estate and life sciences investors.
The fund targets a broad ecosystem within life sciences, including biotechnology firms, pharmaceutical companies, medical technology developers, genetics research operations, and medical equipment manufacturers. Capital will be deployed across two strategic directions: financing existing projects already in Breakthrough's portfolio and funding new campus development and acquisition opportunities throughout the United States and Europe. This geographic and sectoral diversification reflects the global nature of life sciences innovation and manufacturing.
Breakthrough's leadership attributed the fundraise's success to demonstrated market strength in the life sciences sector. Dan Belldegrun, co-founder and CEO, stated that the company established the fund "with the aim of creating and operating cutting-edge environments where life science entrepreneurs and researchers can optimize their quest for life-saving treatments." Belldegrun emphasized that the past two years have validated life sciences as both a financially sound and socially impactful investment area, noting that the fund would continue developing specialized facilities offering comprehensive support services tailored to the long-term operational needs of biotech innovators.
The oversubscription of this fund reflects institutional investor confidence in the life sciences real estate thesis, capitalizing on sustained demand from high-growth biotechnology and corporate biopharma sectors seeking purpose-built laboratory and manufacturing facilities. The scale of this raise signals that specialized life sciences real estate has matured into a distinct asset class attracting significant capital from both real estate and life sciences investors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.